June 2019 - Volume 3 - Issue S1 - Contributor Index

Author:
H Jones, P.
Author:
Haaber, J.
Author:
Haas, R.

PF311 ISOLATED PRIMARY ADRENAL LYMPHOMA (IPAL) - AN EMERGING LYMPHOMA ENTITY? RESULTS OF A RETROSPECTIVE MULTICENTER STUDY

Majidi, F.; Martino, S.; Kondakci, M.; More

HemaSphere. 3(S1):108, June 2019.

Author:
Haas, S.

S137 DNA METHYLATION DYNAMICS IDENTIFY LINEAGE-SPECIFIC REGULATION PATTERNS OF HEMATOPOIETIC DIFFERENTIATION

Stäble, S.; Krämer, S.; Langstein, J.; More

HemaSphere. 3(S1):20, June 2019.

Author:
Haas, V.

PS937 RANDOMIZED PHASE III HOVON-100 STUDY OF CLOFARABINE COMBINED WITH STANDARD TREATMENT IN ADULT PATIENTS WITH NEWLY DIAGNOSED ALL

Rijneveld, A.; van der Holt, B.; de Weerdt, O.; More

HemaSphere. 3(S1):421-422, June 2019.

Author:
Haase, D.
Author:
Haase, M.

PF311 ISOLATED PRIMARY ADRENAL LYMPHOMA (IPAL) - AN EMERGING LYMPHOMA ENTITY? RESULTS OF A RETROSPECTIVE MULTICENTER STUDY

Majidi, F.; Martino, S.; Kondakci, M.; More

HemaSphere. 3(S1):108, June 2019.

Author:
Habermann, T.
Author:
Habets, R.
Author:
Haboubi, T.
Author:
Habra, M.A.

PF311 ISOLATED PRIMARY ADRENAL LYMPHOMA (IPAL) - AN EMERGING LYMPHOMA ENTITY? RESULTS OF A RETROSPECTIVE MULTICENTER STUDY

Majidi, F.; Martino, S.; Kondakci, M.; More

HemaSphere. 3(S1):108, June 2019.

Author:
hachicha, M.

PS1245 NIVOLUMAB FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: LONG TERM RESULTS OF MULTI-CENTER EXPERIENCE IN TURKEY

Ferhanoglu, B.; Ozbalak, M.; Bekoz, H.; More

HemaSphere. 3(S1):567-568, June 2019.

Author:
Hadar, E.

PF334 EPIDURAL/SPINAL ANESTHESIA IN PREGNANT JEWISH ASHKENAZI WOMEN HETEROZYGOTES FOR FACTOR XI DEFICIENCY, A SINGLE CENTER PROSPECTIVE STUDY

Shacham Abulafia, A.; Yaniv, Y.; Steimatzky, A.; More

HemaSphere. 3(S1):119, June 2019.

Author:
Haddadeen, M.
Author:
Hadjiev, E.

PS1131 HIGH-THROUGHPUT B-CELL IMMUNOPROFILING AT DIAGNOSIS AND RELAPSE OFFERS FURTHER EVIDENCE OF FUNCTIONAL SELECTION THROUGHOUT THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA

Vardi, A.; Vlachonikola, E.; Mourati, S.; More

HemaSphere. 3(S1):512, June 2019.

Author:
Haertle, L.

PS1001 HACE1, A NOVEL TUMOR SUPPRESSOR GENE WHICH REGULATE THE RESPONSE OF VENETOCLAX, GANT61 AND NECROPTOSIS ACTIVATORS BY CONTROLLING C-FLIP, GLI2 AND BCL2 GENES IN ACUTE MYELOID LEUKEMIA

Garitano, A.; Teufel, E.; Kreckel, J.; More

HemaSphere. 3(S1):450, June 2019.

Author:
Haferlach, C.

S129 TP53 SOMATIC MUTATIONS AS PRE-LEUKEMIC EVENTS IN ACUTE LYMPHOBLASTIC LEUKEMIA

Chitadze, G.; Stengel, A.; John-Klaua, C.; More

HemaSphere. 3(S1):16-17, June 2019.

PF532 INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

Morimoto, S.; Makishima, H.; Nagata, Y.; More

HemaSphere. 3(S1):218-219, June 2019.

PS1133 GENOMIC ARRAYS IDENTIFY HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA WITH GENOMIC COMPLEXITY: A MULTI-CENTER STUDY

Leeksma, A.; Baliakas, P.; Moysiadis, T.; More

HemaSphere. 3(S1):513, June 2019.

Author:
Haferlach, T.

PF532 INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

Morimoto, S.; Makishima, H.; Nagata, Y.; More

HemaSphere. 3(S1):218-219, June 2019.

PS1327 PRO-NECROPTOTIC RIPK3 AS A STAGE-DEPENDENT MARKER IN THE BONE MARROW OF PATIENTS WITH MDS AND CMML

Dill, V.; Jilg, S.; Wagner, C.; More

HemaSphere. 3(S1):605-606, June 2019.

S1611 MARS: MUTATION-ADJUSTED RISK SCORE FOR ADVANCED SYSTEMIC MASTOCYTOSIS

Jawhar, M.; Schwaab, J.; Álvarez-Twose, I.; More

HemaSphere. 3(S1):742-743, June 2019.

Author:
Hagberg, O.

PS1032 SURVIVAL FROM ACUTE MYELOID LEUKEMIA HAS SINCE 1997 IMPROVED ONLY IN MALES AGED 50–75 YEARS – A SWEDISH POPULATION-BASED STUDY

Juliusson, G.; Hagberg, O.; Lazarevic, V.; More

HemaSphere. 3(S1):466, June 2019.

Author:
Hagedoorn, R.
Author:
Hageman, L.
Author:
Hagemeister, F.

PS1561 RITUXIMAB-BEAM AND AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR PATIENTS (PTS) WITH RELAPSED FOLLICULAR LYMPHOMA (FL) NOT ABLE TO RECEIVE AN ALLOGENEIC SCT: 8-YEAR MEDIAN FOLLOW-UP RESULTS

Khouri, I.; Milton, D.; Young, K.; More

HemaSphere. 3(S1):720, June 2019.

Author:
Hagiwara, S.
Author:
Haider, R.Z.H.
Author:
Haidouri, S.
Author:
Haioun, C.

PS1410 DARATUMUMAB IS WELL TOLERATED AND INDUCES A RAPID HEMATOLOGICAL RESPONSE IN NON IG-M LIGHT CHAIN AMYLOIDOSIS WITH SEVERE CARDIAC IMPAIRMENT

Gounot, R.; Lemonnier, F.; Dupuis, J.; More

HemaSphere. 3(S1):648, June 2019.

S1600 REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM

Thieblemont, C.; Legouill, S.; Di Blasi, R.; More

HemaSphere. 3(S1):736-737, June 2019.

PB1893 NON-INTERVENTIONAL RETROSPECTIVE MULTICENTER STUDY EVALUATING REAL WORD IDELALISIB USE IN CLL AND INHL PATIENTS ENROLLED IN THE FRENCH EARLY ACCESS PROGRAM (EAP)

Ysebaert, L.; Feugier, P.; Salles, G.; More

HemaSphere. 3(S1):862-863, June 2019.

Author:
Hajduk, A.

PF350 CONSTRUCTION OF A PROGNOSTIC MODEL FOR HLH IN ADULTS – ANALYSIS FROM THE PALG HLH IN ADULTS DATABASE

Machowicz, R.; Staniak, M.; Waszczuk-Gajda, A.; More

HemaSphere. 3(S1):126-127, June 2019.

Author:
Hajek, R.

PF601 EVOLVING TREATMENT PATTERNS IN MULTIPLE MYELOMA (MM) DIFFER BY AGE AND REGION: ANALYSIS FROM INSIGHT MM, A GLOBAL, PROSPECTIVE, OBSERVATIONAL STUDY

Chari, A.; Weisel, K.C.; Usmani, S.Z.; More

HemaSphere. 3(S1):254, June 2019.

PF602 OUTCOME OF EXTRA-MEDULLARY DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NEW DRUGS

Montefusco, V.; Gay, F.; Spada, S.; More

HemaSphere. 3(S1):254-255, June 2019.

PF608 ANCHOR (OP-104): A PHASE 1 STUDY UPDATE OF MELFLUFEN AND DEXAMETHASONE PLUS BORTEZOMIB OR DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS REFRACTORY TO AN IMID OR A PROTEASOME INHIBITOR

Pour, L.; Efebera, Y.A.; Granell, M.; More

HemaSphere. 3(S1):257-258, June 2019.

PS1349 UPDATED RISK STRATIFICATION MODEL FOR SMOLDERING MULTIPLE MYELOMA (SMM) INCORPORATING THE REVISED IMWG DIAGNOSTIC CRITERIA

Mateos, M.-V.; Kumar, S.; Gonzalez, V.; More

HemaSphere. 3(S1):616, June 2019.

PS1419 COMPARATIVE EFFECTIVENESS OF TRIPLETS CONTAINING BORTEZOMIB (B), CARFILZOMIB (C), DARATUMUMAB (D), OR IXAZOMIB (I) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN ROUTINE CARE IN THE US

Davies, F.; Rifkin, R.; Costello, C.; More

HemaSphere. 3(S1):652-653, June 2019.

PS1509 QUALITY OF LIFE IN PATIENTS WITH RRMM DURING IXA-THAL-DEX INDUCTION AND IXAZOMIB MAINTENANCE THERAPY IN COMPARISON TO THE GENERAL POPULATION

Ludwig, H.; Pönisch, W.; Knop, S.; More

HemaSphere. 3(S1):695-696, June 2019.

Author:
Hájek, R.
Author:
Hakimeh, D.
Author:
Hakmi, A.
Author:
Halder, R.
Author:
Halka, J.

PS1065 OPEN-LABEL STUDY OF GILTERITINIB, GILTERITINIB PLUS AZACITIDINE, OR AZACITIDINE ALONE IN NEWLY DIAGNOSED FLT3-MUTATED AML PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY: RESULTS FROM THE SAFETY COHORT

Esteve, J.; Schots, R.; Del Castillo, T. Bernal; More

HemaSphere. 3(S1):482, June 2019.

Author:
Halkes, C.

PF761 REDUCED INTENSITY CONDITIONING REGIMEN WITH ALEMTUZUMAB BASED T CELL DEPLETION ENABLES EARLY POST-TRANSPLANTATION CELLULAR INTERVENTION RESTORING GRAFT VERSUS LEUKEMIA EFFECTS IN OLDER AML PATIENTS

Koster, E.; von dem Borne, P.; Bogers, L.; More

HemaSphere. 3(S1):334-335, June 2019.

Author:
Halkes, S.

PS937 RANDOMIZED PHASE III HOVON-100 STUDY OF CLOFARABINE COMBINED WITH STANDARD TREATMENT IN ADULT PATIENTS WITH NEWLY DIAGNOSED ALL

Rijneveld, A.; van der Holt, B.; de Weerdt, O.; More

HemaSphere. 3(S1):421-422, June 2019.

PS1121 ABSENCE OF GPI-NEGATIVE CELLS AT DIAGNOSIS AND LOW NEUTROPHIL COUNT 2 MONTHS AFTER ATGAM BASED TREATMENT ARE ASSOCIATED WITH LOWER 6-MONTH RESPONSE RATE IN ADULTS WITH (VERY) SEVERE APLASTIC ANEMIA

Tjon, J.; Bogers, L.; Wreede, L. de; More

HemaSphere. 3(S1):507-508, June 2019.

Author:
Hall, C.

PF691 SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA: DO CHANGING TREATMENT PATTERNS FOR ITP AFFECT OUTCOMES? DATA FROM THE UK ITP REGISTRY

Todd, S.; Infirri, S. Sardo; Miah, H.; More

HemaSphere. 3(S1):299-300, June 2019.

S838 TRANSFUSION DEPENDENCY IS ASSOCIATED WITH PRESENCE OF TOXIC IRON SPECIES AND INFERIOR SURVIVAL IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES

Hoeks, M.; Bagguley, T.; Roelofs, R.; More

HemaSphere. 3(S1):373, June 2019.

Author:
Hall, R.
Author:
Hallal, M.
Author:
Hallam, S.
Author:
Hallek, M.

S105 GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY

Tausch, E.; Bahlo, J.; Robrecht, S.; More

HemaSphere. 3(S1):4, June 2019.

S106 HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL

Al-Sawaf, O.; Lilienweiss, E.; Bahlo, J.; More

HemaSphere. 3(S1):4-5, June 2019.

S149 FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PROGRESSION-FREE SURVIVAL AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES

Fischer, K.; Al-Sawaf, O.; Bahlo, J.; More

HemaSphere. 3(S1):26-27, June 2019.

Author:
Halpern, A.B.

PF253 SAFETY AND RESOURCE UTILIZATION FOLLOWING EARLY HOSPITAL DISCHARGE AFTER INDUCTION CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA (AML): A 4-YEAR RETROSPECTIVE ANALYSIS

Howard, N.P.; Halpern, A.B.; Othus, M.; More

HemaSphere. 3(S1):78, June 2019.

Author:
Haltner, A.

PF564 OUTCOMES OF PATIENTS WITH T(11;14) MULTIPLE MYELOMA: AN INTERNATIONAL MYELOMA WORKING GROUP MULTICENTER STUDY

Kumar, S.; Goldschmidt, H.; Mateos, M.-V.; More

HemaSphere. 3(S1):234-235, June 2019.

Author:
Halton, E.

S1634 A PHASE I FIRST-IN-HUMAN CLINICAL TRIAL OF CD19-TARGETED 19–28Z/4–1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION

Palomba, M.L.; Batlevi, C.; Riviere, I.; More

HemaSphere. 3(S1):755, June 2019.

Author:
Halvorsen, B.
Author:
Hamada, S.